Loading...
•
Mar 31, 2023
Arcutis Q1 2023 Earnings Report
Arcutis reported first quarter 2023 financial results and provided a business update.
Key Takeaways
Arcutis Biotherapeutics reported net revenues of $2.8 million for ZORYVE in Q1 2023, with prescription growth nearly doubling quarter-over-quarter. The company's NDA for roflumilast foam was accepted by the FDA, and enrollment was completed in the INTEGUMENT-PED trial. Arcutis had approximately $333 million in cash, cash equivalents, and marketable securities.
Net revenues of $2.8 million for ZORYVE in Q1 2023, with unit demand growth nearly doubling quarter-over-quarter.
Commercial payer coverage for ZORYVE expanded to over 110 million commercial lives in the United States.
Health Canada approved ZORYVE for plaque psoriasis, with launch expected in the coming weeks.
FDA accepted NDA for roflumilast foam for seborrheic dermatitis, with a target action date of December 16, 2023.
Forward Guidance
Arcutis anticipates submitting a supplemental New Drug Application (sNDA) to the FDA for ages 6 and above late in the third quarter or early in the fourth quarter of 2023. The Company anticipates potential FDA approval in the fourth quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...